MTOR and Hyperglycemia: Management guideline goals for patients with cancer who develop mTOR inhibitor-associated hyperlipidaemia (elevations in total cholesterol, low-density lipoprotein, and triglyceride levels) or hyperglycemia are to decrease short-term morbidity associated with these AEs.20